SPARC shares jump 20% on Sezaby PRV win, 60-day appeal

Stock jumps after US court backs SPARC on PRV

Shares of Sun Pharma Advanced Research Company Ltd (SPARC) rallied sharply in Tuesday’s trade after a favourable ruling from a US court on a Priority Review Voucher (PRV) linked to Sezaby. The stock surged 20% to hit its upper price band of Rs 161.10. Despite the day’s move, SPARC remains down 19.73% on a year-to-date (YTD) basis.

SPARC informed exchanges that the US District Court for the District of Columbia granted summary judgment in its favour in the matter concerning the issuance of the PRV tied to Sezaby’s approval. The ruling is important because PRVs are considered valuable regulatory assets in the pharmaceutical industry. The case also involves Sun Pharmaceutical Industries, Inc., which was listed as a plaintiff along with SPARC in the court record.

What the court held in the Sezaby PRV dispute

In its filing to the BSE, SPARC said the court held that the US Food and Drug Administration’s (FDA) withholding of the PRV was contrary to law. The key finding, as described by the company, was that no drug product containing phenobarbital sodium was “previously approved” as that term is used in the relevant statute.

The court order provided a 60-day window to appeal the decision. SPARC CEO Anil Raghavan said the company was pleased with the ruling, adding that it validated SPARC’s long-held position on the matter. The dispute traces back to the FDA’s earlier decision to withhold the PRV even though Sezaby had received approval.

Why Priority Review Vouchers matter to drugmakers

A PRV entitles the holder to an expedited six-month timeline for a future drug application. The court document described this benefit as being worth tens of millions of dollars.

For companies developing multiple products, a PRV can shorten the regulatory review cycle on a future submission, making it strategically meaningful. PRVs can also be viewed as balance-sheet relevant assets given their value in the ecosystem, although the immediate impact depends on how a company chooses to use the voucher.

Sezaby: product details and FDA approval

Sezaby is a benzyl alcohol and propylene glycol-free formulation of phenobarbital sodium powder for injection. It was approved by the US FDA for the treatment of neonatal seizures, a condition described in the case record as affecting babies under four weeks old.

The court record states that SPARC and Sun Pharmaceutical Industries, Inc. received FDA approval for Sezaby on November 17, 2022. The same approval communication also conveyed the FDA’s decision to deny the rare pediatric disease PRV request.

What triggered the PRV denial and the legal challenge

The dispute centred on a statutory criterion for receiving a PRV. Among the criteria referenced in the court record is that the new drug cannot contain an active moiety that has been “previously approved” under specific pathways.

The FDA denied the PRV on the ground that phenobarbital sodium, the active moiety in Sezaby, was “previously approved.” The court disagreed with that interpretation on the facts and statutory reading discussed in the judgment, concluding that the FDA’s withholding of the voucher was contrary to law.

Share price reaction: what markets priced in

The stock’s move to the upper circuit reflected investor focus on the potential value and optionality associated with a PRV in the US market. While the session gain was 20%, the stock’s YTD decline of 19.73% indicates that the rally came after prior weakness.

For shareholders, the immediate takeaway is that the legal uncertainty around the voucher moved meaningfully in SPARC’s favour at the district court level. The next swing factor is procedural, with the 60-day window available for an appeal.

Promoter holding snapshot

As of September 2025, promoters held a 65.67% stake in SPARC, according to the information provided. Ownership levels matter in situations involving high-impact regulatory or legal outcomes because they shape liquidity dynamics and market sensitivity to news flow.

Regulatory context: why US compliance history still gets attention

The broader Sun Pharma group has faced US regulatory scrutiny over manufacturing compliance in prior years, as reflected in the additional material provided. For example, Sun’s Halol facility has been linked to regulatory actions and product-level consequences, including instances where the FDA assessed compliance status and referenced Current Good Manufacturing Practice (cGMP) expectations.

SPARC has also dealt with USFDA process outcomes in other programs, including Complete Response Letters (CRLs) and appeal decisions in unrelated applications, as noted in the supplied text. While those items are separate from Sezaby’s PRV litigation, they form part of the backdrop investors often track when assessing US-facing product pipelines and execution risk.

Key facts at a glance

Market impact and why the ruling matters

The ruling matters because it addresses whether the FDA acted lawfully when it declined to issue a PRV following Sezaby’s approval. If a PRV is ultimately issued and usable, it could provide SPARC with an expedited review option for a future drug application, which the court record notes is a benefit worth tens of millions of dollars.

For the market, the event is primarily about regulatory optionality and the value of time in drug approvals. The sharp, circuit-level move suggests investors quickly repriced the probability of SPARC securing the voucher after the district court decision. However, the presence of a defined 60-day appeal window means the process may not be finished.

Conclusion

SPARC’s shares hit the upper circuit after the US District Court for the District of Columbia ruled in its favour on the PRV linked to Sezaby, holding that the FDA’s withholding of the voucher was contrary to law. The court has provided a 60-day window for an appeal.

The next key milestone is whether an appeal is filed and how the PRV process proceeds following the judgment, based on further regulatory and legal updates from the parties involved.